Trial Profile
An Open-Label, Single-Dose, Randomized, Four-Way Crossover Study In Healthy Volunteers To Evaluate The Effects Of Caloric Content And Time Of Dosing On The Pharmacokinetics Of Pregabalin Controlled Release Formulation As Compared To The Immediate Release Formulation.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Jan 2021
Price :
$35
*
At a glance
- Drugs Pregabalin (Primary) ; Pregabalin
- Indications Fibromyalgia; Generalised anxiety disorder; Neuropathic pain; Partial epilepsies; Postherpetic neuralgia; Tonic-clonic epilepsy
- Focus Pharmacokinetics
- Sponsors Pfizer
- 13 May 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Mar 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 15 Feb 2011 New trial record